Rockefeller Capital Management’s Rani Therapeutics RANI Stock Holding History

Rockefeller Capital Management’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.78K	Buy	+11,545	New	+$10.2K	﹤0.01%	4062

Other funds holding RANI

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Rockefeller Capital Management's RANI Position: Q2 2026 in Review

Rockefeller Capital Management opened a new position in Rani Therapeutics (RANI) in Q2 2026: 11,545 shares worth $8.78K. The stake represents ﹤0.01% of the portfolio and ranks #4062 among its holdings.

68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

Rockefeller Capital Management held 11,545 shares of Rani Therapeutics worth $8.78K as of Q2 2026.
Rani Therapeutics was a new Rockefeller Capital Management position in Q2 2026.
Rani Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4062 holding.
68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.